Senescent cell treatment could combat age-related diseases 20 October 2021 | By Anna Begley (Drug Target Review) Scientists have developed a novel technique for the targeted clearance of senescent cells to improve treatments for ageing and other conditions.
Scientists identify protein that prevents HSV-1 brain damage 20 October 2021 | By Anna Begley (Drug Target Review) Mammalian target of rapamycin complex 2 (mTORC2) was found to prevent brain damage in mice infected with herpes simplex virus 1 (HSV-1).
Medicenna’s MDNA11 a promising alternative to checkpoint inhibitors 19 October 2021 | By Anna Begley (Drug Target Review) Medicenna's IL-2 super-agonist, MDNA11, successfully induced antitumour cells in animal models, a pre-clinical study has revealed.
Antibiotic-free hydrogel fights against drug-resistant bacteria 19 October 2021 | By Anna Begley (Drug Target Review) New dendritic hydrogels were tested against several infectious bacteria and could be used as an an antibiotic-free treatment in the future.
3D printed microneedle vaccine shows promise in animals 19 October 2021 | By Victoria Rees (Drug Target Review) Researchers have shown that a new microneedle vaccine patch was 10 times stronger at generating an immune response in animals than a subcutaneous injection.
Highly potent antiviral against dengue could prevent spread of virus 18 October 2021 | By Victoria Rees (Drug Target Review) A new antiviral has shown promise against the dengue virus in mice and has the potential to be used as a preventative measure.
New single-cell and metagenomic technique can characterise microbes 14 October 2021 | By Anna Begley (Drug Target Review) The metagenomic method, termed SMAGLinker, could improve the accuracy and resolution of microbial characterisation to improve medicine design.
Measuring microRNAs in blood may indicate dementia risk 14 October 2021 | By Anna Begley (Drug Target Review) Researchers identified three microRNAs whose levels were associated with mental performance in cells, mice and humans.
Mission Therapeutics receives $500k grant for Parkinson’s research 14 October 2021 | By Anna Begley (Drug Target Review) Mission Therapeutics was granted $500,000 from the The Michael J Fox Foundation for Parkinson’s Research for DUB inhibitor testing.
Neurolysin shown to be potential drug target for ischemic stroke 13 October 2021 | By Anna Begley (Drug Target Review) Researchers are identifying molecules that interact with neurolysin, a peptidase that helps protect the brain against stroke.
Scientists uncover answer to colorectal cancer immunotherapy resistance 13 October 2021 | By Anna Begley (Drug Target Review) Boosting dendritic cells prevented immunotherapy resistance in mouse models, suggesting a new approach to colorectal cancer therapies.
Wyss Centre initiates collaboration to improve brain tumour treatment 13 October 2021 | By Anna Begley (Drug Target Review) The Wyss Centre has announced a collaborative project to improve understanding of the brain cancer glioblastoma and develop new personalised therapies.
New vaccination approach could target “core” of all coronaviruses 12 October 2021 | By Anna Begley (Drug Target Review) Researchers have used genetically engineered SARS-CoV-2 Spike proteins to boost antibodies against a range of coronaviruses in mice.
Discovery unveils genetic risk factor shared by Alzheimer’s and COVID-19 12 October 2021 | By Anna Begley (Drug Target Review) Scientists have identified the OAS1 gene as a risk factor for both Alzheimer's disease and COVID-19, suggesting potential drug targets.
Stem cell therapy repairs injured peripheral nerves in animal models 12 October 2021 | By Anna Begley (Drug Target Review) Gingiva-derived mesenchymal stem cells were used to surgically repair injured peripheral nerves, showing potential for new therapies.
